Commentary · 27 May 2026
Conference abstractPublished 13 Sep 2017
Pancreatic cancer, the most lethal cancer today
University of Kentucky Markey Cancer Center, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Pancreatic cancer is the most aggressive, most lethal cancer in medicine today. The American Cancer Society has estimated that there will be 53,670 new diagnoses of pancreatic cancer and 43,090 deaths in 2017. Those numbers will propel pancreatic cancer to the number three cancer killer, which spot has been held by breast cancer for many years. The overall 5-year survival is less than 10%, but in patients who have received curative resection, the 5-year survival extends to 20%. Pancreas Cancer Action Network has estimated that as a result of the aging population, it will be the number 2 cancer killer by 2025, second only to lung cancer. It has long been accepted that pancreatic cancer is a disease of the elderly. However, there is a subset of much younger individuals who are being diagnosed well before the age of 60. It appears that approximately 10-15% of all individuals diagnosed with pancreatic cancer are below the 60-year-old assumed minimum. The objective of this study is to determine whether there are common genetic mutations, common risk factors, or common past medical factors. The common risk factors in older patients are age and coronary artery disease, but younger patients would not have these diseases. It is important to determine what the younger onset individuals have in common. This will be a secondary analysis of genomic data in the largest cohort of pancreatic cancer patients ever assembled to ferret out the similarities and differences between early onset and normal onset of pancreatic cancer.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.
More from this journal
The newest in Pancreatic Disorders & Therapy.
Short communication · 27 May 2026
Immunometabolic Interactions in Pancreatic Disease: Crosstalk Between Energy Dysregulation, Immune Activation, and Tissue Dysfunction
Commentary · 27 May 2026
Microvascular Dysfunction in Pancreatic Disorders: Endothelial Injury, Perfusion Failure, and Tissue Consequences
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPancreatic Disorders & Therapy
- SubjectGastroenterology & Hepatology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Sally Hodges”
